MEDXF - Medexus Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Medexus Pharmaceuticals Inc.

35 Nixon Road
Unit 1
Bolton, ON L7E 1K1
877 633 3987

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees100

Key executives

NameTitlePayExercisedYear born
Mr. Kenneth d'EntremontCEO & Director592kN/AN/A
Mr. Marcel KonradChief Financial Officer405.77kN/A1976
Ms. Tina Byers CFAExec. of Investor RelationsN/AN/AN/A
Mr. Ian C. Wildgoose BrownGen. Counsel & Corp. Sec.N/AN/AN/A
Mr. Bill PoncySr. VP of Commercial Operations - United StatesN/AN/AN/A
Mr. Brian PetersVP of Sales & Marketing - United StatesN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Corporate governance

Medexus Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.